Tvardi Therapeutics (TVRD) EPS (Weighted Average and Diluted) (2020 - 2025)
Tvardi Therapeutics' EPS (Weighted Average and Diluted) history spans 8 years, with the latest figure at -$0.76 for Q4 2025.
- On a quarterly basis, EPS (Weighted Average and Diluted) rose 84.62% to -$0.76 in Q4 2025 year-over-year; TTM through Dec 2025 was -$5.57, a 81.45% increase, with the full-year FY2025 number at -$3.26, up 71.45% from a year prior.
- EPS (Weighted Average and Diluted) hit -$0.76 in Q4 2025 for Tvardi Therapeutics, down from -$0.59 in the prior quarter.
- Over the last five years, EPS (Weighted Average and Diluted) for TVRD hit a ceiling of -$0.02 in Q3 2021 and a floor of -$24.67 in Q4 2023.
- Historically, EPS (Weighted Average and Diluted) has averaged -$4.14 across 5 years, with a median of -$0.62 in 2021.
- Biggest five-year swings in EPS (Weighted Average and Diluted): surged 94.29% in 2021 and later crashed 4030.61% in 2024.
- Tracing TVRD's EPS (Weighted Average and Diluted) over 5 years: stood at -$0.64 in 2021, then tumbled by 2726.56% to -$18.09 in 2022, then tumbled by 36.37% to -$24.67 in 2023, then skyrocketed by 79.98% to -$4.94 in 2024, then surged by 84.62% to -$0.76 in 2025.
- Business Quant data shows EPS (Weighted Average and Diluted) for TVRD at -$0.76 in Q4 2025, -$0.59 in Q3 2025, and -$1.0 in Q2 2025.